Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 75 of 178 entries
View as:

Ketoconazole Administration: How it is Affected by the Body and Broken Down and How it Acts on the Body When Used With Velcade

Phase: N/A Priority: Normal
NCT ID: NCT00129207 Org: User:
Start: - End: - Due: -

Study of MLN4924 Plus Azacitidine in Treatment-naive Participants With Acute Myelogenous Leukemia (AML) Who Are 60 Years or Older

Phase: N/A Priority: Normal
NCT ID: NCT01814826 Org: User:
Start: 04/10/13 End: 04/08/18 Due: 04/08/19

IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT01850524 Org: User:
Start: 04/29/13 End: 06/24/22 Due: 06/24/23

Study of MLN4924, a Novel Inhibitor of Nedd8 Activating Enzyme, in Adult Patients With Lymphoma or Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT00722488 Org: User:
Start: 06/30/08 End: 09/30/13 Due: 09/30/14

Safety and Efficacy Study of TAK-700 in Patients With Nonmetastatic Castration-resistant Prostate Cancer and a Rising Prostate-specific Antigen

Phase: N/A Priority: Normal
NCT ID: NCT01046916 Org: User:
Start: 05/31/10 End: 03/31/13 Due: 03/31/14

Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT01425008 Org: User:
Start: 09/15/11 End: 10/16/18 Due: 10/16/19

Pharmacokinetics Study of Oral IXAZOMIB in Participants With Advanced Nonhematologic Malignancies or Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT01454076 Org: User:
Start: 11/10/11 End: 06/16/16 Due: 06/16/17

Docetaxel With or Without TAK-117 (MLN1117) in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02393209 Org: User:
Start: 06/03/15 End: 01/20/17 Due: 01/20/18

Mifamurtide (L-MTP-PE) for High-Risk Osteosarcoma

Phase: N/A Priority: Normal
NCT ID: NCT00631631 Org: User:
Start: 01/31/08 End: 10/31/12 Due: 10/31/13

Phase I Dose Escalation Study of VELCADE Plus Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00064636 Org: User:
Start: 12/31/02 End: - Due: -

A Study of Sapanisertib, Combination of Sapanisertib With MLN1117, Paclitaxel and Combination of Sapanisertib With Paclitaxel in Women With Endometrial Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02725268 Org: User:
Start: 04/01/16 End: 10/30/20 Due: 10/30/21

MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00911066 Org: User:
Start: 06/30/09 End: 10/31/13 Due: 10/31/14

A Study to Evaluate the Effects of Pevonedistat on the Corrected QT (QTc) Interval in Participants With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT03330106 Org: User:
Start: 11/15/17 End: 06/21/21 Due: 06/21/22

A Study to Assess the Relative Bioavailability, Effect of Food, and Gastric Potential Hydrogen (pH) Modification on the Pharmacokinetics (PK) of TAK-931 in Participants With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT03708211 Org: User:
Start: 03/28/19 End: 12/03/19 Due: 12/03/20

A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT01950364 Org: User:
Start: 11/30/13 End: 06/30/15 Due: 06/30/16

A Study to Evaluate the Effects of Rifampin on Pharmacokinetics (PK) of Pevonedistat in Participants With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT03486314 Org: User:
Start: 08/13/18 End: 02/28/21 Due: 02/28/22

Study of the Safety and Efficacy of MLN1202 in Patients in Multiple Sclerosis

Phase: N/A Priority: Normal
NCT ID: NCT01199640 Org: User:
Start: 05/31/05 End: 10/31/07 Due: 10/31/08

Study Evaluating the Safety and Tolerability of Weekly Dosing of Oral IXAZOMIB in Adult Patients With Relapsed and Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT00963820 Org: User:
Start: 10/31/09 End: 01/31/14 Due: 01/31/15

Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT02367352 Org: User:
Start: 03/19/15 End: 05/23/17 Due: 05/23/18

Study of the Combination of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT01040871 Org: User:
Start: 01/31/10 End: 08/31/12 Due: 08/31/13

A Dose-Finding Study of Vedolizumab for Treatment of Steroid-Refractory Acute Intestinal Graft-Versus-Host Disease (GvHD) in Participants Who Have Undergone Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT)

Phase: N/A Priority: Normal
NCT ID: NCT02993783 Org: User:
Start: 04/28/17 End: 05/09/18 Due: 05/09/19

Open-Label Phase 1/2 Study of VELCADE for Injection in Patients With Light-chain (AL)-Amyloidosis

Phase: N/A Priority: Normal
NCT ID: NCT00298766 Org: User:
Start: 06/30/05 End: 09/30/09 Due: 09/30/10

Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis

Phase: N/A Priority: Normal
NCT ID: NCT01659658 Org: User:
Start: 12/26/12 End: 07/11/22 Due: 07/11/23

Surveillance Study of Patients With Newly Diagnosed Osteosarcoma

Phase: N/A Priority: Normal
NCT ID: NCT01194284 Org: User:
Start: 12/31/11 End: 12/31/13 Due: 12/31/14

MLN2704 in Subjects With Metastatic Androgen-Independent Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00070837 Org: User:
Start: 10/31/03 End: 10/31/04 Due: 10/31/05